Biogen (NASDAQ:BIIB) Receives Daily Media Sentiment Rating of 0.19
Headlines about Biogen (NASDAQ:BIIB) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Biogen earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.8905010592419 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the headlines that may have effected Accern’s rankings:
- Biogen Inc (BIIB) Needle Moving on Volume – Evergreen Caller (evergreencaller.com)
- Primed for Breakout or Bust? A look at Biogen Inc. (NASDAQ:BIIB) and Duke Energy Corporation (NYSE:DUK) – FLBC News (flbcnews.com)
- Biogen Inc. (BIIB) has a value of $291.01 per share While Acceleron Pharma Inc. (XLRN) is stand at $35.39 – Stocks Gallery (stocksgallery.com)
- Noteworthy ETF Inflows: VHT, TMO, BIIB, AET – Nasdaq (nasdaq.com)
- Sumitomo Mitsui Trust Holdings, Inc. Raises Its Ownership in Biogen Inc. (BIIB) Stock – Modern Readers (modernreaders.com)
BIIB has been the subject of a number of research reports. Robert W. Baird reissued a “neutral” rating and set a $290.00 target price on shares of Biogen in a research note on Tuesday, April 18th. Mizuho reaffirmed a “hold” rating and issued a $290.00 price objective on shares of Biogen in a research note on Tuesday, April 18th. Barclays PLC reaffirmed an “overweight” rating and issued a $360.00 price objective (down previously from $380.00) on shares of Biogen in a research note on Sunday, April 23rd. Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $310.00 price objective on shares of Biogen in a research note on Tuesday, April 25th. Finally, Cantor Fitzgerald set a $278.00 price objective on shares of Biogen and gave the company a “hold” rating in a research note on Tuesday, April 25th. Eleven investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. Biogen currently has an average rating of “Buy” and an average price target of $329.74.
Biogen (NASDAQ BIIB) traded down 0.18% during mid-day trading on Wednesday, reaching $288.74. 777,522 shares of the company were exchanged. The stock has a market capitalization of $61.05 billion, a price-to-earnings ratio of 18.95 and a beta of 0.79. The company’s 50 day moving average price is $278.73 and its 200-day moving average price is $273.77. Biogen has a 12-month low of $244.28 and a 12-month high of $329.83.
Biogen (NASDAQ:BIIB) last released its earnings results on Tuesday, July 25th. The biotechnology company reported $5.04 EPS for the quarter, beating the consensus estimate of $4.36 by $0.68. Biogen had a net margin of 28.10% and a return on equity of 37.42%. The firm had revenue of $3.08 billion for the quarter, compared to analyst estimates of $2.81 billion. During the same period last year, the firm earned $5.21 EPS. The business’s quarterly revenue was up 6.4% compared to the same quarter last year. On average, equities research analysts forecast that Biogen will post $21.44 earnings per share for the current fiscal year.
In other Biogen news, Director Brian S. Posner sold 1,084 shares of the firm’s stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $256.31, for a total value of $277,840.04. Following the transaction, the director now directly owns 6,330 shares of the company’s stock, valued at approximately $1,622,442.30. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Susan H. Alexander sold 4,974 shares of the firm’s stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $290.01, for a total transaction of $1,442,509.74. Following the completion of the transaction, the executive vice president now directly owns 22,258 shares in the company, valued at $6,455,042.58. The disclosure for this sale can be found here. Over the last three months, insiders sold 13,816 shares of company stock worth $3,931,380. Insiders own 0.32% of the company’s stock.
WARNING: This piece of content was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.watchlistnews.com/biogen-nasdaqbiib-receives-daily-media-sentiment-rating-of-0-19/1466638.html.
Biogen Company Profile
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.